Viewing Study NCT04702360


Ignite Creation Date: 2025-12-25 @ 2:03 AM
Ignite Modification Date: 2025-12-27 @ 9:12 AM
Study NCT ID: NCT04702360
Status: APPROVED_FOR_MARKETING
Last Update Posted: 2021-07-15
First Post: 2021-01-06
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation
Sponsor: Vertex Pharmaceuticals Incorporated
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module